Abstract
The objective of the Genome-based Therapeutic Drugs for Depression study is to investigate the function of variations in genes encoding key proteins in serotonin, norepinephrine, neurotrophic and glucocorticoid signaling in determining the response to serotonin-reuptake-inhibiting and norepinephrine-reuptake-inhibiting antidepressants. A total of 116 single nucleotide polymorphisms in 10 candidate genes were genotyped in 760 adult patients with moderate-to-severe depression, treated with escitalopram (a serotonin reuptake inhibitor) or nortriptyline (a norepinephrine reuptake inhibitor) for 12 weeks in an open-label part-randomized multicenter study. The effect of genetic variants on change in depressive symptoms was evaluated using mixed linear models. Several variants in a serotonin receptor gene (HTR2A) predicted response to escitalopram with one marker (rs9316233) explaining 1.1% of variance (P=0.0016). Variants in the norepinephrine transporter gene (SLC6A2) predicted response to nortriptyline, and variants in the glucocorticoid receptor gene (NR3C1) predicted response to both antidepressants. Two HTR2A markers remained significant after hypothesis-wide correction for multiple testing. A false discovery rate of 0.106 for the three strongest associations indicated that the multiple findings are unlikely to be false positives. The pattern of associations indicated a degree of specificity with variants in genes encoding proteins in serotonin signaling influencing response to the serotonin-reuptake-inhibiting escitalopram, genes encoding proteins in norepinephrine signaling influencing response to the norepinephrine-reuptake-inhibiting nortriptyline and a common pathway gene influencing response to both antidepressants. The single marker associations explained only a small proportion of variance in response to antidepressants, indicating a need for a multivariate approach to prediction.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study
BMC Medicine Open Access 26 July 2022
-
Gene expression studies in Depression development and treatment: an overview of the underlying molecular mechanisms and biological processes to identify biomarkers
Translational Psychiatry Open Access 08 June 2021
-
Corticotropin releasing hormone receptor CRHR1 gene is associated with tianeptine antidepressant response in a large sample of outpatients from real-life settings
Translational Psychiatry Open Access 05 November 2020
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout

References
Franchini L, Serretti A, Gasperini M, Smeraldi E . Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 1998; 32: 255–259.
Serretti A, Kato M, De Ronchi D, Kinoshita T . Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12: 247–257.
Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA 2006; 296: 1609–1618.
McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006; 78: 804–814.
Kato M, Serretti A . Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2008; published ahead of print 4 November 2008; doi:10.1038/mp.2008.116.
van Rossum EF, Binder EB, Majer M, Koper JW, Ising M, Modell S et al. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry 2006; 59: 681–688.
Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004; 36: 1319–1325.
Wong ML, Whelan F, Deloukas P, Whittaker P, Delgado M, Cantor RM et al. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci USA 2006; 103: 15124–15129.
Uher R, Maier W, Hauser J, Marusic A, Schmael C, Mors O et al. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 2009; 194: 252–259.
Huezo-Diaz P, Uher R, Smith R, Rietschel M, Henigsberg N, Marusic A et al. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry 2009; 195.
Landen M, Thase ME . A model to explain the therapeutic effects of serotonin reuptake inhibitors: the role of 5-HT2 receptors. Psychopharmacol Bull 2006; 39: 147–166.
Goring HH, Terwilliger JD, Blangero J . Large upward bias in estimation of locus-specific effects from genomewide scans. Am J Hum Genet 2001; 69: 1357–1369.
Pariante CM, Miller AH . Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49: 391–404.
Uher R, Farmer A, Maier W, Rietschel M, Hauser J, Marusic A et al. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med 2008; 38: 289–300.
Mulder RT, Joyce PR, Frampton C . Relationships among measures of treatment outcome in depressed patients. J Affect Disord 2003; 76: 127–135.
Mathew CG . New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat Rev Genet 2008; 9: 9–14.
Dadd T, Weale ME, Lewis CM . A critical evaluation of genomic control methods for genetic association studies. Genet Epidemiol 2008; published ahead of print 1 December 2008; doi: 10.1002/gepi.20379.
Wing JK, Sartorius N, Ustin TB . Diagnosis and Clinical Measurement in Psychiatry. A Reference Manual for SCAN. World Health Organization, Geneva, Switzerland, 1998.
Sanchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 2003; 167: 353–362.
Sanchez C, Hyttel J . Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999; 19: 467–489.
Montgomery SA, Asberg M . A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389.
Hamilton M . Development of a rating scale for primary depressive illness. Brit J Clin Psychol 1967; 6: 278–296.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J . An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–571.
Freeman B, Smith N, Curtis C, Huckett L, Mill J, Craig IW . DNA from buccal swabs recruited by mail: evaluation of storage effects on long-term stability and suitability for multiplex polymerase chain reaction genotyping. Behav Genet 2003; 33: 67–72.
De Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D . Efficiency and power in genetic association studies. Nat Genet 2005; 37: 1217–1223.
Solovyev VV, Shahmuradov IA . PromH: promoters identification using orthologous genomic sequences. Nucleic Acids Res 2003; 31: 3540–3545.
Wellcome Trust Case Control Consortium. Genome-wide association study of 14 000 cases of seven common diseases and 3000 shared controls. Nature 2007; 447: 661–678.
Wittke-Thompson JK, Pluzhnikov A, Cox NJ . Rational inferences about departures from Hardy–Weinberg equilibrium. Am J Hum Genet 2005; 76: 967–986.
Lane P . Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat 2008; 7: 93–106.
Mallinckrodt CH, Clark WS, David SR . Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001; 11: 9–21.
StataCorp. Stata Statistical Software: Release 10. StataCorp LP, College Station, Texas, 2007.
Li J, Ji L . Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 2005; 95: 221–227.
Nyholt DR . A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765–769.
Benjamini Y, Hochberg Y . Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57: 289–300.
Sabatti C, Service S, Freimer N . False discovery rate in linkage and association genome screens for complex disorders. Genetics 2003; 164: 829–833.
Storey JD, Tibshirani R . Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440–9445.
Kall L, Storey JD, MacCoss MJ, Noble WS . Posterior error probabilities and false discovery rates: two sides of the same coin. J Proteome Res 2008; 7: 40–44.
Gauderman WJ, Morrison JM . Quanto 1.1: a computer program for power and sample size calculations for genetic-epigemiology studies. http://hydrauscedu/gxe, 2006.
Seldin MF, Shigeta R, Villoslada P, Selmi C, Tuomilehto J, Silva G et al. European population substructure: clustering of northern and southern populations. PLoS Genet 2006; 2: e143.
Falush D, Stephens M, Pritchard JK . Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics 2003; 164: 1567–1587.
Devlin B, Roeder K . Genomic control for association studies. Biometrics 1999; 55: 997–1004.
Acknowledgements
The GENDEP study was funded by the European Commission Framework 6 grant, EC Contract Ref. LSHB-CT-2003-503428. Lundbeck provided both nortriptyline and escitalopram free of charge for the GENDEP study. The Biomedical Research Centre for Mental Health at the Institute of Psychiatry, King's College London and South London and Maudsley NHS Foundation Trust (funded by the National Institute for Health Research, Department of Health, UK) and GlaxoSmithKline contributed by funding add-on projects in the London center. The funders had no role in the design and conduct of the study, in data collection, analysis, interpretation or writing the report. We acknowledge the contributions of Andrej Marusic and Jorge Perez, who were the lead investigators at Ljubljana, Slovenia and at Brescia, Italy, and who passed away during the conduct of the study. We also acknowledge the contribution of the following collaborators: Helen Dean, Amanda Elkin, Bhanu Gupta, Cerisse Gunasinghe, Desmond Campbell, Richard J Williamson, David Dempster, Julien Mendlewicz, Maja Bajs, Jana Strohmaier, Christine Schmäl, Susanne Höfels, Anna Schuhmacher, Ute Pfeiffer, Sandra Weber, Anne Schinkel Stamp, Alenka Tancic, Jerneja Sveticic, Zrnka Kovacic, Paweł Kapelski, Maria Skibiñska, Aleksandra Rajewska, Anna Leszczynska, Aleksandra Szczepankiewicz, Elzbieta Cegielska, Laura Pedrini, Cristian Bonvicini, Luciana Rillosi, Sylvie Linotte, Borut Jerman, Tina Žagar and Metka Paragi.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on The Pharmacogenomics Journal website (http://www.nature.com/tpj)
Supplementary information
Rights and permissions
About this article
Cite this article
Uher, R., Huezo-Diaz, P., Perroud, N. et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 9, 225–233 (2009). https://doi.org/10.1038/tpj.2009.12
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2009.12
Keywords
This article is cited by
-
Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study
BMC Medicine (2022)
-
Gene expression studies in Depression development and treatment: an overview of the underlying molecular mechanisms and biological processes to identify biomarkers
Translational Psychiatry (2021)
-
Serotonergic receptor gene polymorphism and response to selective serotonin reuptake inhibitors in ethnic Malay patients with first episode of major depressive disorder
The Pharmacogenomics Journal (2021)
-
Corticotropin releasing hormone receptor CRHR1 gene is associated with tianeptine antidepressant response in a large sample of outpatients from real-life settings
Translational Psychiatry (2020)
-
Association between functional polymorphisms in serotonin transporter gene (SLC6A4) and escitalopram treatment response in depressive patients in a South Indian population
European Journal of Clinical Pharmacology (2020)